DexCom Inc., a global leader in glucose biosensing, has announced that its new feature, Dexcom Smart Basal, is currently under review by both the FDA and CE mark. This feature is an integrated titration module designed to simplify basal insulin initiation and management for users. The announcement was made during the 61st annual European Association for the Study of Diabetes (EASD) Conference, where DexCom also highlighted the positive impact of its glucose biosensing technology on health outcomes and cost-effectiveness for people with diabetes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250915690916) on September 15, 2025, and is solely responsible for the information contained therein.